Show simple item record

dc.contributor.authorKingston, B.
dc.contributor.authorCutts, R. J.
dc.contributor.authorBye, H.
dc.contributor.authorBeaney, M.
dc.contributor.authorWalsh-Crestani, G.
dc.contributor.authorHrebien, S.
dc.contributor.authorSwift, C.
dc.contributor.authorKilburn, L. S.
dc.contributor.authorKernaghan, S.
dc.contributor.authorMoretti, L.
dc.contributor.authorWilkinson, K.
dc.contributor.authorWardley, Andrew M
dc.contributor.authorMacpherson, I. R.
dc.contributor.authorBaird, R. D.
dc.contributor.authorRoylance, R.
dc.contributor.authorReis-Filho, J. S.
dc.contributor.authorHubank, M.
dc.contributor.authorFaull, I.
dc.contributor.authorBanks, K. C.
dc.contributor.authorLanman, R. B.
dc.contributor.authorGarcia-Murillas, I.
dc.contributor.authorBliss, J. M.
dc.contributor.authorRing, A.
dc.contributor.authorTurner, N. C.
dc.date.accessioned2021-05-18T08:48:09Z
dc.date.available2021-05-18T08:48:09Z
dc.date.issued2021en
dc.identifier.citationKingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021 Apr 23;12(1).en
dc.identifier.pmid33893289en
dc.identifier.doi10.1038/s41467-021-22605-2en
dc.identifier.urihttp://hdl.handle.net/10541/624021
dc.description.abstractThe genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating tumour DNA sequencing to interrogate the genomic profile of ABC in 800 patients in the plasmaMATCH trial. We demonstrate diverse subclonal resistance mutations, including enrichment of HER2 mutations in HER2 positive disease, co-occurring ESR1 and MAP kinase pathway mutations in HR + HER2- disease that associate with poor overall survival (p = 0.0092), and multiple PIK3CA mutations in HR + disease that associate with short progression free survival on fulvestrant (p = 0.0036). The fraction of cancer with a mutation, the clonal dominance of a mutation, varied between genes, and within hotspot mutations of ESR1 and PIK3CA. In ER-positive breast cancer subclonal mutations were enriched in an APOBEC mutational signature, with second hit PIK3CA mutations acquired subclonally and at sites characteristic of APOBEC mutagenesis. This study utilises circulating tumour DNA analysis in a large clinical trial to demonstrate the subclonal diversification of pre-treated advanced breast cancer, identifying distinct mutational processes in advanced ER-positive breast cancer, and novel therapeutic opportunities.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41467-021-22605-2en
dc.titleGenomic profile of advanced breast cancer in circulating tumour DNAen
dc.typeArticleen
dc.contributor.departmentThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Londonen
dc.identifier.journalNature Communicationsen
dc.description.noteen
refterms.dateFOA2021-05-19T08:51:01Z


Files in this item

Thumbnail
Name:
33893289.pdf
Size:
1.438Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record